John brings more than 25 years of small molecule drug discovery and development experience to the company, primarily in the areas of immunology, inflammation, oncology, and metabolic disease. Prior to joining Ventyx, John was Vice President of Drug Discovery at the Ferring Research Institute where he was responsible for global drug discovery activities. John also previously served as Senior Vice President of Chemistry at Exelixis. Under his leadership, his teams have advanced more than 30 molecules into the clinic. He is the co-inventor of the approved therapeutics COMETRIQ®/CABOMETYX® and MINNEBRO®, and led the team that discovered COTELLIC®. Earlier in his career he held positions of increasing responsibility in discovery at Chiron and served as an Assistant Professor of Chemistry at the University of California, Riverside. John has more than 80 publications and 30 issued patents. He received a bachelor’s degree in chemistry from the University of Kansas, a PhD in organic chemistry from the University of Wisconsin, Madison, and was an NIH postdoctoral fellow in organic synthesis at Stanford University.
Chief Scientific Officer